# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products fo...
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate...
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products fo...
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly sales of $143.600 million which missed the analyst consensus estimate...
M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with...